Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 9.17
ATRC's Cash to Debt is ranked higher than
68% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.42 vs. ATRC: 9.17 )
ATRC' s 10-Year Cash to Debt Range
Min: 1.42   Max: No Debt
Current: 9.17

Equity to Asset 0.84
ATRC's Equity to Asset is ranked higher than
86% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. ATRC: 0.84 )
ATRC' s 10-Year Equity to Asset Range
Min: -2.52   Max: 0.87
Current: 0.84

-2.52
0.87
F-Score: 2
Z-Score: 14.82
M-Score: -2.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -12.07
ATRC's Operating margin (%) is ranked lower than
73% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.85 vs. ATRC: -12.07 )
ATRC' s 10-Year Operating margin (%) Range
Min: -15700   Max: -5.41
Current: -12.07

-15700
-5.41
Net-margin (%) -12.24
ATRC's Net-margin (%) is ranked lower than
74% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.03 vs. ATRC: -12.24 )
ATRC' s 10-Year Net-margin (%) Range
Min: -17980   Max: -6.43
Current: -12.24

-17980
-6.43
ROE (%) -10.36
ATRC's ROE (%) is ranked lower than
72% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.27 vs. ATRC: -10.36 )
ATRC' s 10-Year ROE (%) Range
Min: -160.02   Max: -15.8
Current: -10.36

-160.02
-15.8
ROA (%) -8.79
ATRC's ROA (%) is ranked lower than
73% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.87 vs. ATRC: -8.79 )
ATRC' s 10-Year ROA (%) Range
Min: -91.98   Max: -11.04
Current: -8.79

-91.98
-11.04
ROC (Joel Greenblatt) (%) -58.87
ATRC's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.74 vs. ATRC: -58.87 )
ATRC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -294.69   Max: -33.57
Current: -58.87

-294.69
-33.57
Revenue Growth (3Y)(%) -0.30
ATRC's Revenue Growth (3Y)(%) is ranked lower than
67% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ATRC: -0.30 )
ATRC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -29.9   Max: 915.8
Current: -0.3

-29.9
915.8
EBITDA Growth (3Y)(%) 35.20
ATRC's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. ATRC: 35.20 )
ATRC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -62.7   Max: 120.7
Current: 35.2

-62.7
120.7
EPS Growth (3Y)(%) 20.30
ATRC's EPS Growth (3Y)(%) is ranked higher than
71% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.20 vs. ATRC: 20.30 )
ATRC' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.4   Max: 36.3
Current: 20.3

-45.4
36.3
» ATRC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ATRC Guru Trades in Q2 2014

RS Investment Management 843,638 sh (+38.19%)
Steven Cohen 300,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

ATRC Guru Trades in Q3 2014

RS Investment Management 862,738 sh (+2.26%)
Steven Cohen Sold Out
» More
Q4 2014

ATRC Guru Trades in Q4 2014

RS Investment Management 1,054,238 sh (+22.20%)
» More
Q1 2015

ATRC Guru Trades in Q1 2015

Chuck Royce 363,000 sh (New)
RS Investment Management 1,174,830 sh (+11.44%)
» More
» Details

Insider Trades

Latest Guru Trades with ATRC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.90
ATRC's P/B is ranked lower than
97% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. ATRC: 4.90 )
ATRC' s 10-Year P/B Range
Min: 0.64   Max: 14.1
Current: 4.9

0.64
14.1
P/S 5.22
ATRC's P/S is ranked lower than
120% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.75 vs. ATRC: 5.22 )
ATRC' s 10-Year P/S Range
Min: 0.27   Max: 5.53
Current: 5.22

0.27
5.53
Current Ratio 3.79
ATRC's Current Ratio is ranked higher than
74% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.55 vs. ATRC: 3.79 )
ATRC' s 10-Year Current Ratio Range
Min: 1.43   Max: 7.58
Current: 3.79

1.43
7.58
Quick Ratio 3.18
ATRC's Quick Ratio is ranked higher than
75% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. ATRC: 3.18 )
ATRC' s 10-Year Quick Ratio Range
Min: 1.14   Max: 7.18
Current: 3.18

1.14
7.18
Days Inventory 151.24
ATRC's Days Inventory is ranked lower than
63% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 121.06 vs. ATRC: 151.24 )
ATRC' s 10-Year Days Inventory Range
Min: 38.13   Max: 160.74
Current: 151.24

38.13
160.74
Days Sales Outstanding 64.20
ATRC's Days Sales Outstanding is ranked lower than
56% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.58 vs. ATRC: 64.20 )
ATRC' s 10-Year Days Sales Outstanding Range
Min: 43.02   Max: 67.09
Current: 64.2

43.02
67.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.00
ATRC's Price/Net Cash is ranked lower than
89% of the 47 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.00 vs. ATRC: 20.00 )
ATRC' s 10-Year Price/Net Cash Range
Min: 4.55   Max: 43.11
Current: 20

4.55
43.11
Price/Net Current Asset Value 11.60
ATRC's Price/Net Current Asset Value is ranked lower than
74% of the 69 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. ATRC: 11.60 )
ATRC' s 10-Year Price/Net Current Asset Value Range
Min: 1.03   Max: 32.77
Current: 11.6

1.03
32.77
Price/Tangible Book 7.30
ATRC's Price/Tangible Book is ranked lower than
96% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. ATRC: 7.30 )
ATRC' s 10-Year Price/Tangible Book Range
Min: 0.85   Max: 16.1
Current: 7.3

0.85
16.1
Price/DCF (Projected) 70.40
ATRC's Price/DCF (Projected) is ranked lower than
148% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. ATRC: 70.40 )
ATRC' s 10-Year Price/DCF (Projected) Range
Min: 0.29   Max: 66.1
Current: 70.4

0.29
66.1
Price/Median PS Value 2.10
ATRC's Price/Median PS Value is ranked lower than
123% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.00 vs. ATRC: 2.10 )
ATRC' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 2.01
Current: 2.1

0.13
2.01
Earnings Yield (Greenblatt) -2.40
ATRC's Earnings Yield (Greenblatt) is ranked lower than
73% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ATRC: -2.40 )
ATRC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.9   Max: 0
Current: -2.4

-3.9
0

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:A5I.Germany,
AtriCure Inc was incorporated in the State of Delaware as AtriCure, Inc. on October 31, 2000. It is a medical device company and engaged in developing, manufacturing and selling cardiac surgical ablation systems designed to create precise lesions, in cardiac, or heart, tissue for the treatment of atrial fibrillation, and systems for the exclusion of the left atrial appendage. It has two primary product lines for the ablation of cardiac tissue. Its primary product line for the ablation of cardiac tissue is the AtriCure Synergy Ablation System ('Synergy System'), a bipolar ablation clamp system and related radiofrequency ('RF') ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. Additionally, the Company offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System ('AtriClip System'), which is designed to safely and effectively exclude the left atrial appendage. Its products are utilized by cardiothoracic surgeons during concomitant open-heart surgical procedures and also during sole-therapy minimally invasive cardiac ablation procedures. During a concomitant open procedure, the surgeon ablates cardiac tissue and/or excludes the left atrial appendage, secondary, or concomitant, to a primary cardiac procedure such as a valve or coronary bypass. Additionally, cardiothoracic surgeons have adopted its products as a treatment alternative for AF patients who may be candidates for sole-therapy minimally invasive surgical procedures. Its Synergy System, which includes its Isolator Synergy clamps, a radiofrequency generator and related switchbox, is cleared by the FDA, for the treatment of patients with persistent and long-standing persistent AF during open-heart concomitant coronary artery bypass grafting and/or valve replacement or repair procedures. In the United States it primarily sells its products to medical centers through its direct sales force. AtriCure Europe, B.V., its wholly-owned subsidiary incorporated and based in the Netherlands, markets and sells its products throughout Europe, the Middle East and Africa, or EMEA, primarily through distributors, while in certain markets, such as Germany and the Benelux region, it sell directly to medical centers. Additionally, it sells its products to other international distributors, mainly in Asia, South America and Canada. The Company's competitors include Biosense Webster, Inc. (a subsidiary of Johnson & Johnson), St. Jude Medical, Inc., and Medtronic, Inc. Its products are medical devices and are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries.
» More Articles for ATRC

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Amyris, AtriCure, 3D Systems Corporation and Cooper Tire & Rubber Compan Sep 10 2012 
AtriCure Inc. (ATRC) President and CEO and Director David J Drachman sells 40,671 Shares Feb 25 2011 
AtriCure Inc. Reports Operating Results (10-Q) Aug 10 2010 
AtriCure Inc. Reports Operating Results (10-Q) Nov 09 2009 
AtriCure Inc. Reports Operating Results (10-Q) Aug 10 2009 
AtriCure Reports Second Quarter 2009 Financial Results Aug 04 2009 
AtriCure Inc. Reports Operating Results (10-Q) May 07 2009 
AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2008 Financial Resul Feb 09 2009 

More From Other Websites
ATRICURE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 21 2015
ATRICURE, INC. Financials May 08 2015
Can AtriCure (ATRC) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape May 07 2015
4 Big-Volume Stocks to Trade for Breakouts May 04 2015
10-Q for AtriCure, Inc. May 03 2015
ATRICURE, INC. Files SEC form 10-Q, Quarterly Report May 01 2015
AtriCure reports 1Q loss Apr 29 2015
AtriCure reports 1Q loss Apr 29 2015
AtriCure Inc Earnings Call scheduled for 4:30 pm ET today Apr 29 2015
AtriCure Reports First Quarter 2015 Financial Results and Updates 2015 Outlook Apr 29 2015
ATRICURE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 29 2015
AtriCure Reports First Quarter 2015 Financial Results and Updates 2015 Outlook Apr 29 2015
Q1 2015 AtriCure Inc Earnings Release - After Market Close Apr 29 2015
Is a Surprise Coming for AtriCure (ATRC) This Earnings Season? - Tale of the Tape Apr 28 2015
Zacks Rank #5 Additions for Thursday - Tale of the Tape Apr 23 2015
AtriClip System Surpasses 50,000 Units Sold Worldwide Apr 21 2015
AtriClip System Surpasses 50,000 Units Sold Worldwide Apr 21 2015
AtriCure to Announce First Quarter 2015 Financial Results Apr 09 2015
AtriCure to Announce First Quarter 2015 Financial Results Apr 08 2015
AATS Graham Foundation and AtriCure Announce James L. Cox Fellowship in Atrial Fibrillation Surgery Apr 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK